Abstract
Background
Congenital Heart Disease (CHD) impacts roughly 1% of newborns worldwide, necessitating multifaceted treatment strategies that often include medication therapy. 1 However, dose-dependent medications in patients with CHD raise the risk of drug-related side effects, posing significant challenges to effective medication management. 2 Common medications used in children with CHD include diuretics, anti-arrhythmic, ACE inhibitors, beta-blockers, and anticoagulants, each of these plays a crucial role in managing heart function, but also comes with potential side effects. 3
Diuretics like Furosemide help to manage fluid overload, but can also cause dehydration and electrolyte imbalances, leading to potential kidney issues. Anti-arrhythmic drugs such as Digoxin support heart function, but carry risks of toxicity, which can manifest as nausea, or vomiting. ACE inhibitors like Enalapril reduce blood pressure and heart strain, but may cause hypotension, kidney dysfunction, and hyperkalemia. Beta-blockers like Propranolol manage arrhythmias, but can lead to bradycardia, fatigue, respiratory issues, and limit physical activity. Anticoagulants such as Warfarin prevent clots, but increase bleeding risk, necessitating regular blood monitoring.3,4 These side effects can significantly impact a child’s quality of life, leading to frequent hospital visits, stress, and reduced medication adherence. The need for ongoing monitoring and the potential for complications also place a substantial burden on healthcare systems, particularly in resource-limited settings. 4 Addressing these drug-related side effects in children with CHD is critical. A comprehensive approach involving personalized dosing, careful monitoring, and patient education is essential to mitigate risks and improve outcomes, thereby reducing the overall strain on both families and healthcare systems. 4
This policy brief helps to generate clinical protocols specifically for the pediatric patients with CHD. The target audiences are health managers, policy makers, and healthcare professionals involved in the care of these patients. By providing evidence-based recommendations tailored to the clinical settings, the brief aims to influence and enhance practices within healthcare institutions to ensure safer and more effective medication management.
The brief underscores the importance of addressing medication-related challenges in CHD management by highlighting the prevalence and impact of these issues. Effective medication management is paramount for improving outcomes and reducing complications in children with CHD. By presenting evidence-based policy options such as standardized protocols, electronic health record utilization, personalized dosing adjustments, patient education, and specialized care teams, policymakers can be more effective in implementing measures to enhance medication management and improve health outcomes for children with CHD.
Analysis
The analysis underpinning this policy brief is based on the evidence derived from a comprehensive scoping review, 4 which focused on drug-related side effects in children with CHD. This scoping review was conducted using the framework proposed by Arksey and O'Malley 5 and the PRISMA-ScR guidelines. The review aimed to investigate ADRs in children with CHD.
A systematic search was conducted without timeframe limitations, covering studies published up to November 1, 2023. Inclusion criteria were strictly set to capture studies reporting drug-related side effects in children with CHD, and non-English studies, research focused on adults, and studies unrelated to CHD or drug side effects were excluded. The results of this review were critically analyzed to identify the key challenges and gaps in medication management for this vulnerable population.
The evidence derived from the scoping review directly informed the formulation of the policy options presented in this brief. The analysis underpinning this policy brief incorporates evidence from studies conducted across low, middle, and high-income countries. This global approach ensures that the findings and recommendations are applicable to a diverse range of healthcare settings. Each policy recommendation was derived from the identified drug-related side effects and their implications for health outcomes.
Policy Implications
To address the complexities of medication management for children with CHD, the following policy options are proposed to improve outcomes, reduce side effects, and enhance the overall quality of care. Each option is evaluated based on its expected impact, anticipated costs, and the pathways for successful implementation (Table 1). These options are critical to guiding health policymakers, hospital managers, and healthcare professionals in making informed decisions.
Summary of the Policy Options.
Abbreviations: EHR, Electronic Health records; CHD, Congenital Heart Disease; IT, Information Technology.
Options 1: Establishing Standardized Protocols
Standardized protocols are anticipated to significantly reduce medication errors, streamline care processes, and improve the consistency of care across different healthcare facilities. This will likely lead to better health outcomes and reduce complications for children with CHD. The initial costs will include the development of protocols, training of healthcare professionals, and ongoing updates to maintain protocol relevance. However, long-term cost savings are expected due to the reduction in complications and hospital readmissions. Successful implementation requires collaboration between healthcare organizations, professional bodies, and clinicians. These stakeholders should ensure that protocols are culturally sensitive and adaptable to local contexts. Regular monitoring and updates are essential to maintain the effectiveness of these protocols.
Options 2: Using EHRs
EHRs offer a centralized platform for tracking a child’s medication use, interactions, and side effects. The use of EHRs will facilitate comprehensive tracking of medication use, interactions, and side effects, improve communication among healthcare providers and support making informed decisions. This is expected to reduce medication-related errors and improve patient outcomes. Significant upfront investments are required for software development, implementation, information technology infrastructure, and staff training. Ongoing costs will include maintenance and data security measures. EHR implementation requires strong IT support and training programs to ensure that all healthcare providers can effectively use the system. Policymakers must address potential disparities in access to EHRs by ensuring that all healthcare facilities, regardless of resource availability, can implement and maintain these systems.
Options 3: Personalized Dosing Adjustments
Personalized dosing adjustments can significantly reduce drug-related side effects and improve treatment efficacy by tailoring medication dosages to individual patient needs. This approach is expected to enhance the precision of care and overall health outcomes. Personalized dosing requires increased monitoring, frequent consultations, and potentially higher initial costs. However, these costs may be offset by long-term savings from reduced side effects and hospitalizations. Implementation demands the integration of personalized dosing into routine clinical practice, supported by continuous training and updated clinical guidelines. Equity considerations must be addressed to ensure that all children with CHD, regardless of socioeconomic status, have access to necessary monitoring and personalized care.
Options 4: Patient Education and Shared Decision-Making
Educating patients and caregivers through patient education and shared decision-making will empower them to participate in medication management actively leading to better health outcomes. This collaborative approach is anticipated to reduce the burden on healthcare systems by minimizing unnecessary hospital visits. Developing and delivering educational programs require significant resources, including the creation of culturally and linguistically appropriate materials. The cost-effectiveness of this approach depends on the successful engagement of patients and caregivers. Healthcare professionals must integrate education into routine care, ensuring that materials are accessible and relevant to diverse patient populations. Collaboration with patient advocacy groups and the use of digital platforms can enhance the reach and impact of educational initiatives.
Options 5: Specialized Cardiology-Pharmacotherapy Teams
The formation of specialized cardiology-pharmacotherapy teams is expected to optimize medication management, reduce complications, and improve long-term outcomes for children with CHD by combining the expertise of cardiologists and pharmacotherapists. The formation of these teams involves significant initial investment in training and ongoing support. However, long-term savings are expected through the reduction of complications and hospital readmissions. The success of this policy option hinges on the strategic placement of teams across various regions to ensure equitable access. Healthcare organizations must invest in the formation and continuous support of these teams, with a focus on ensuring accessibility for all children with CHD, regardless of geographic or socioeconomic barriers.
Further Important Considerations and Research Recommendations
Important considerations for the implementation of policy options to improve medication management for children with CHD include robust monitoring and evaluation mechanisms to track implementation effectiveness, identifying barriers and facilitating factors, establishing a timeline for updates, and planning for next steps such as the development of additional educational resources. Monitoring should focus on key performance indicators like adherence to standardized protocols and utilization of EHRs. Overcoming barriers like resource constraints and disparities in access requires strategies like stakeholder engagement and cultural competence training. Regular updates to the policy brief ensure relevance and responsiveness to evolving healthcare landscapes.
Gaps in knowledge underscore the need for further research to inform evidence-based practice in CHD care. Studies should explore personalized dosing strategies, the potential of analyzing personal health records, and the long-term effects of chronic medication use. Additionally, investigating the role of advanced technologies, such as mobile health applications, could enhance adherence and monitoring. These efforts will collectively improve medication management, ultimately benefiting the health and well-being of children with CHD. Overall, systematic implementation coupled with ongoing adaptation and collaboration among stakeholders will maximize the impact of policy options on improving medication management and health outcomes for children with CHD.
Footnotes
Author Contributions
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by the Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran (Grant Number:1402-2-113-26934).
